Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer

Código QR

Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer

Guardado en:

Detalles Bibliográficos
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/839aaab9b4554eddb78c18a7f48b942e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
por: Leisha A Emens, et al.
Publicado: (2021)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Julia Foldi, et al.
Publicado: (2021)

Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
por: Yizhao Xie, et al.
Publicado: (2021)

Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer
por: Craig Davison, et al.
Publicado: (2021)

A triple negative breast cancer: what it is not!
por: Katakkar SB
Publicado: (2012)

Triple negative breast cancer: an Indian perspective
por: Akhtar M, et al.
Publicado: (2015)

Molecular heterogeneity in adjacent cells in triple-negative breast cancer
por: Huebschman ML, et al.
Publicado: (2015)

Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer
por: Paolo Peterlongo, et al.
Publicado: (2021)

Co-dependency for MET and FGFR1 in basal triple-negative breast cancers
por: Vanessa Y. C. Sung, et al.
Publicado: (2021)

Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
por: Corey Speers, et al.
Publicado: (2017)

A DNA methylation-based liquid biopsy for triple-negative breast cancer
por: Katrina Cristall, et al.
Publicado: (2021)

RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis
por: Zhuming Yin, et al.
Publicado: (2021)

Correction: MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer
Publicado: (2021)

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
por: Hanne Vos, et al.
Publicado: (2021)

Dramatic Reduction of Distant Pancreatic Metastases Using Local Light Activation of Verteporfin with Nab-Paclitaxel
por: Michael Pigula, et al.
Publicado: (2021)

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
por: Nina Radosevic-Robin, et al.
Publicado: (2021)

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
por: Otto Metzger-Filho, et al.
Publicado: (2021)

The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer
por: Zhenbo Tu, et al.
Publicado: (2021)

Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis
por: Sixten Harborg, et al.
Publicado: (2021)

Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
por: Maitri Kalra, et al.
Publicado: (2021)

Locoregional recurrence of triple-negative breast cancer: effect of type of surgery and adjuvant postoperative radiotherapy
por: Bayoumi Y, et al.
Publicado: (2014)

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women
por: Vinayak W Patil, et al.
Publicado: (2011)

Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial
por: Gunn Huh, et al.
Publicado: (2021)

Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome
por: Juliana C. Wortman, et al.
Publicado: (2021)

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study
por: Romualdo Barroso-Sousa, et al.
Publicado: (2021)

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
por: Thomas M, et al.
Publicado: (2017)

OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer
por: Jonas Steenbrugge, et al.
Publicado: (2021)

Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients
por: Yves Boucher, et al.
Publicado: (2021)

Metabolic reprogramming underlies metastatic potential in an obesity-responsive murine model of metastatic triple negative breast cancer
por: Ciara H. O’Flanagan, et al.
Publicado: (2017)

Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer
por: Wei-Gang Qiu, et al.
Publicado: (2017)

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
por: Yu-Hsiang Chen, et al.
Publicado: (2017)

Systemic immune reaction in axillary lymph nodes adds to tumor-infiltrating lymphocytes in triple-negative breast cancer prognostication
por: Fangfang Liu, et al.
Publicado: (2021)

Oseltamivir phosphate monotherapy ablates tumor neovascularization, growth, and metastasis in mouse model of human triple-negative breast adenocarcinoma
por: Haxho F, et al.
Publicado: (2014)

Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
por: Jeffrey P. Solzak, et al.
Publicado: (2017)

Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
por: Huicheng Liu, et al.
Publicado: (2021)

Pathological Complete Response to Lenvatinib After Failure of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
por: Yusuke Johira, et al.
Publicado: (2021)

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer
por: Abdel Kader Y, et al.
Publicado: (2013)

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
por: Linda T. Vahdat, et al.
Publicado: (2021)

Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy
por: Maria Vittoria Dieci, et al.
Publicado: (2021)

MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer
por: Kwok-Kin Wong, et al.
Publicado: (2021)